Table 1 Baseline characteristics of the study population.
N | 33 |
|---|---|
Sex (%) | |
Male | 51.5 |
Median Age (years) | 11.7 (7.5–14.2) |
Median % of Baseline CD4 counts | 23.0 (19.5–32.0) |
Median % of Baseline CD8 counts (%) | 45.0 (33.5–57.5) |
Median Baseline VL (HIV-RNA Log copies/ml) | 4.0 (3.4–4.6) |
Length of ARV therapy (months) | 83.0 (49.0–119.0) |
Length of PI exposure (months) | 61.0 (38.0–73.0) |
Length of NRTI exposure (months) | 84.0 (49.0–119.0) |
Length of NNRTI exposure (months) | 5.0 (0.0–31.0) |
Median number of previous PI exposure | 2.0 (1–3.0) |
Median number of NAMs | 3.0 (1.5–4.0) |
Median number of protease resistance mutations | 5.0 (2.0–6.5) |